|
1
|
Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1.
|
J Virol Methods
|
2007
|
1.66
|
|
2
|
Tissue distribution of radioactivity following intranasal administration of radioactive microspheres.
|
J Pharm Pharmacol
|
2001
|
1.07
|
|
3
|
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse.
|
Vaccine
|
1998
|
1.03
|
|
4
|
Local and systemic immune response to a microencapsulated sub-unit vaccine for plague.
|
Vaccine
|
1996
|
1.02
|
|
5
|
Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge.
|
Int J Pharm
|
2004
|
0.94
|
|
6
|
Nasal delivery of vaccines.
|
J Drug Target
|
1996
|
0.92
|
|
7
|
Immunisation against plague by transcutaneous and intradermal application of subunit antigens.
|
Vaccine
|
2004
|
0.91
|
|
8
|
Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.
|
Vaccine
|
2000
|
0.91
|
|
9
|
Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines.
|
Vaccine
|
1998
|
0.89
|
|
10
|
Immunological aspects of polymer microsphere vaccine delivery systems.
|
J Drug Target
|
2003
|
0.85
|
|
11
|
Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration.
|
Vaccine
|
2001
|
0.85
|
|
12
|
Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits.
|
J Control Release
|
2000
|
0.84
|
|
13
|
Encapsulation of plasmid DNA in PLGA-stearylamine microspheres: a comparison of solvent evaporation and spray-drying methods.
|
J Microencapsul
|
2003
|
0.83
|
|
14
|
The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles.
|
Biomaterials
|
2008
|
0.83
|
|
15
|
Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
|
Int J Pharm
|
2008
|
0.83
|
|
16
|
Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes.
|
Biochem Pharmacol
|
1985
|
0.83
|
|
17
|
Antimicrobial properties of liposomal polymyxin B.
|
J Antimicrob Chemother
|
1999
|
0.83
|
|
18
|
Adjuvant synergy: the effects of nasal coadministration of adjuvants.
|
Immunol Cell Biol
|
2004
|
0.82
|
|
19
|
Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes.
|
J Pharm Pharmacol
|
2000
|
0.81
|
|
20
|
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume.
|
Int J Pharm
|
1999
|
0.80
|
|
21
|
Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic-hydrophilic copolymers.
|
Eur J Pharm Sci
|
2000
|
0.80
|
|
22
|
Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs.
|
J Pharm Pharmacol
|
1993
|
0.80
|
|
23
|
Mucosal delivery of herpes simplex virus vaccine.
|
Res Virol
|
1992
|
0.80
|
|
24
|
Protection of the enzyme L-asparaginase during lyophilisation--a molecular modelling approach to predict required level of lyoprotectant.
|
Int J Pharm
|
1999
|
0.79
|
|
25
|
Liposomal (MLV) polymyxin B: physicochemical characterization and effect of surface charge and drug association.
|
J Drug Target
|
1993
|
0.79
|
|
26
|
The prolongation of the in vitro dissolution of a soluble drug (phenethicillin potassium) by microencapsulation with ethyl cellulose.
|
J Pharm Pharmacol
|
1981
|
0.79
|
|
27
|
Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-gamma: effect of dose and formulation.
|
Vaccine
|
1998
|
0.79
|
|
28
|
Adjuvant action of melittin following intranasal immunisation with tetanus and diphtheria toxoids.
|
J Drug Target
|
2003
|
0.78
|
|
29
|
New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model.
|
Vaccine
|
2008
|
0.78
|
|
30
|
Streptococcus equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses.
|
Vaccine
|
2008
|
0.78
|
|
31
|
The preparation of liposomes using compressed carbon dioxide: strategies, important considerations and comparison with conventional techniques.
|
J Pharm Pharmacol
|
2006
|
0.78
|
|
32
|
The use of albumin microspheres in the treatment of carrageenan-induced inflammation in the rat.
|
J Pharm Pharmacol
|
1992
|
0.77
|
|
33
|
Immobilisation of vaccines onto micro-crystals for enhanced thermal stability.
|
Int J Pharm
|
2005
|
0.77
|
|
34
|
Oral plasmid DNA delivery systems for genetic immunisation.
|
J Drug Target
|
2003
|
0.76
|
|
35
|
Cholesterol-bile salt vesicles as potential delivery vehicles for drug and vaccine delivery.
|
Int J Pharm
|
2005
|
0.76
|
|
36
|
Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6.
|
Vaccine
|
2002
|
0.76
|
|
37
|
Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis.
|
J Pharm Pharmacol
|
1999
|
0.76
|
|
38
|
Intranasal administration of influenza vaccines: current status.
|
BioDrugs
|
2000
|
0.76
|
|
39
|
Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats.
|
J Pharm Pharmacol
|
1997
|
0.75
|
|
40
|
Expression and stability of herpes simplex virus antigens in Salmonella typhimurium.
|
Adv Exp Med Biol
|
1995
|
0.75
|
|
41
|
The prolongation of the survival times of mice implanted with TLX5 cells by treatment with methotrexate encapsulated in erythrocytes.
|
Biochem Pharmacol
|
1987
|
0.75
|
|
42
|
Stimulation of spleen cells in vitro by nanospheric particles containing antigen.
|
J Control Release
|
2003
|
0.75
|
|
43
|
Effect of suspending agents on the bioavailability of suspensions of sulphathiazole.
|
Farmaco Prat
|
1979
|
0.75
|
|
44
|
Increased resistance of DNA lipoplexes to protein binding in vitro by surface-modification with a multivalent hydrophilic polymer.
|
J Drug Target
|
2004
|
0.75
|
|
45
|
Cellular and humoral responses to microencapsulated Yersinia pestis subunit vaccines following oral delivery.
|
Biochem Soc Trans
|
1997
|
0.75
|
|
46
|
PDLLA microspheres containing steroids: spray-drying, o/w and w/o/w emulsifications as preparation methods.
|
J Microencapsul
|
1998
|
0.75
|
|
47
|
Surface modified polymeric nanoparticles for immunisation against equine strangles.
|
Int J Pharm
|
2009
|
0.75
|
|
48
|
Calorimetric study of bovine serum albumin dilution and adsorption onto polystyrene particles.
|
Int J Pharm
|
2005
|
0.75
|
|
49
|
Poly(lactic acid) microspheres as immunological adjuvants for orally delivered cholera toxin b subunit.
|
Biochem Soc Trans
|
1992
|
0.75
|
|
50
|
Preparation, properties and the effects of free and liposomal tobramycin on siderophore production by Pseudomonas aeruginosa.
|
J Antimicrob Chemother
|
1994
|
0.75
|